VALN vs NVAX vs DYAI vs IBRX vs SIGA

For growth investors, ImmunityBio, Inc.

(IBRX) is the stronger pick with 22. 7% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Valneva SE (VALN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus SIGA Technologies, Inc. at 14. 3x.

Over the past 5 years, SIGA Technologies, Inc.

(SIGA) delivered a total return of +1. 4%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus NVAX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Dyadic International, Inc.

(DYAI) is the lower-risk stock at 0. 98β versus ImmunityBio, Inc. 's 2. 21β — meaning IBRX is approximately 125% more volatile than DYAI relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 2% for Dyadic International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ImmunityBio, Inc.

(IBRX) is pulling ahead at 22. 7% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, IBRX leads at 150. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -28. 0% for ImmunityBio, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -23. 3% for IBRX. At the gross margin level — before operating expenses — IBRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for VALN: 97.

8% to $11. 00.

In this comparison, SIGA (12.

7% yield) pays a dividend. VALN, NVAX, DYAI, IBRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VALN is a small-cap quality compounder stock; NVAX is a small-cap high-growth stock; DYAI is a small-cap high-growth stock; IBRX is a small-cap high-growth stock; SIGA is a small-cap deep-value stock. SIGA pays a dividend while VALN, NVAX, DYAI, IBRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.